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Background and objectives: Alpha-1-antitrypsin deficiency (AATD) is associated with a 
high risk for the development of early-onset emphysema and liver disease. A large majority of 
subjects with severe AATD carry the ZZ genotype, which can be easily detected. Another rare 
pathologic variant, the Mmalton allele, causes a deficiency similar to that of the Z variant, but 
it is not easily recognizable and its detection seems to be underestimated. Therefore, we have 
included a rapid allele-specific genotyping assay for the detection of the Mmalton variant in 
the diagnostic algorithm of AATD used in our laboratory. The objective of this study was to 
test the usefulness of this new algorithm for Mmalton detection.
Materials and methods: We performed a retrospective revision of all AATD determinations 
carried out in our laboratory over 2 years using the new diagnostic algorithm. Samples with a 
phenotype showing one or two M alleles and AAT levels discordant with that phenotype were 
analyzed using the Mmalton allele-specific genotyping assay.
Results: We detected 49 samples with discordant AAT levels; 44 had the MM and five the 
MS phenotype. In nine of these samples, a single rare Mmalton variant was detected. During 
the study period, two family screenings were performed and four additional Mmalton variants 
were identified.
Conclusion: The incorporation of the Mmalton allele-specific genotyping assay in the diagnostic 
algorithm of AATD resulted in a faster and cheaper method to detect this allele and avoided a 
significant delay in diagnosis when a sequencing assay was required. This methodology can be 
adapted to other rare variants. Standardized algorithms are required to obtain conclusive data 
of the real incidence of rare AAT alleles in each region.
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Introduction
Alpha-1-antitrypsin deficiency (AATD) is an autosomal recessive disorder caused 
by several mutations in the alpha-1-antitrypsin (AAT) gene (SERPINA1). The most 
important clinical manifestations of AATD include COPD in adults and liver disorders 
in children as well as in adults.1 Liver disease is mediated by aggregation of misfolded 
AAT molecules to polymers that accumulate within the hepatocytes.2 This results in a 
reduction in the circulating levels of AAT, an excess of neutrophil elastase (the main 
substrate for AAT), and therefore, pulmonary tissue destruction. The SERPINA1 gene 
is located on the long arm of chromosome 14 and is organized in three nonencoding 
(Ia, Ib, and Ic) exons and four (II, III, IV, and V) encoding exons.3 At least 120 vari-
ants of the SERPINA1 gene have been identified, and these variants are codominantly 
inherited and closely associated with specific serum AAT levels.
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The most common normal AAT allele is the M variant, and 
the most frequent deficient variants in Caucasian populations 
are Z (G/A, Glu342Lys) and S (A/T, Glu264Val).4,5 Neverthe-
less, several AAT alleles, other than the Z and S variants, are 
associated with significantly reduced or absent serum AAT 
levels. These deficient variants are called “rare”, with little 
being known about their epidemiology and even less about 
the associated clinical phenotypes.6–8 The Mmalton variant 
is a rare deficiency variant that differs from the normal allele 
by deletion of the entire codon (TTC) for the residue Phe at 
position 51/52 (exon II). It is associated with severe AATD 
and hepatic inclusions due to the formation of polymers9,10 
and is characterized by a normal isoelectrophoretic pattern,11 
which may, at first, be confounded with an M protein.
In a retrospective review of AATD studies performed in 
our laboratory, a remarkably high frequency of the deficient 
I and Mmalton alleles was observed, which together account 
for 54% of all the rare AAT variants in Spain (34% for I and 
20% for Mmalton).7 While the I variant causes moderate 
AATD (60%–70% of normal level), the Mmalton causes a 
deficiency similar to the Z allele and is also considered the 
most common cause of severe AATD in Sardinia (Italy)8 and 
Tunisia,12,13 where it accounts for 60% and 35% of the rare 
variants, respectively. Mmalton represents 8% of the rare 
variants in Switzerland.7
The current laboratory testing for AATD involves the 
determination of a combination of serum AAT levels, AAT 
phenotyping by isoelectrofocusing (IEF), and an allele-
specific genotyping assay for detecting the most prevalent 
deficiency alleles (Z and S).14 Nevertheless, most rare variants 
can only be detected by molecular biology techniques, such 
as genome sequencing, which is not available in all routine 
laboratories.15 Moreover, since Mmalton and other rare 
variants are not easily recognizable, this may contribute to 
misclassification of many of these cases, with the subsequent 
underestimation of their true frequency.16 For this reason, 
in our laboratory, we have recently developed a rapid real-
time polymerase chain reaction (PCR) and melting curves 
assay designed for the detection of the Mmalton allele.17 
This method detects the Mmalton mutation by analysis of 
the melting point of one of the two adjacent fluorescently 
labeled probes. This last probe hybridizes over the mutation 
position and matches perfectly with the mutated sequence 
(deletion of an entire TTC codon). This technology is optimal 
for working with small amounts of DNA, such as dried blood 
spot (DBS) samples and even with residual DNA present 
in serum samples. This technology has been included in 
the diagnostic algorithm of AATD used in our laboratory, 
as follows: AAT levels are determined, and in cases with 
concentrations ,1.16 g/L,18 the phenotype is determined 
by IEF. A specific range of AAT levels was established for 
each of the major phenotypes;19 therefore, if AAT values are 
in accordance with the phenotype observed, the laboratory 
results are considered definitive. If AAT levels are not within 
the range established for their phenotype and the phenotype 
contains one or two M alleles, the Mmalton genotype is 
determined by the allele-specific genotyping assay. In addi-
tion, S and Z alleles are determined by the allele-specific 
genotyping method in order to test possible S and Z variants 
not correctly characterized by phenotyping. If these variants 
are not detected, exonic sequencing of the SERPINA1 gene 
is performed.17 This method consists of amplification of the 
four encoding exons of the SERPINA1 gene by PCR followed 
by Sanger automated sequencing.
Serum samples are needed for the determination of AAT 
levels and IEF, while DNA extracted from whole blood 
samples is necessary for sequencing. Currently, DNA is 
usually obtained from DBS samples14,20 or even from serum 
samples (residual DNA). Nevertheless, when there is dis-
cordance between AAT levels and the IEF phenotype pat-
tern, an additional whole blood or DBS sample is usually 
required for exonic sequencing of the SERPINA1 gene. This 
sample requirement represents an additional venopuncture 
or finger puncture resulting in a significant delay in AATD 
diagnosis. Besides, this additional sample can sometimes not 
be obtained for different reasons: the patient does not return 
to the doctor’s office for the results, delay between results 
and new blood extraction, or disabled individuals. Therefore, 
we have proposed a fast allele-specific genotyping assay for 
the detection of Mmalton, the most prevalent deficient rare 
variant in our population. For this purpose, the same serum 
sample used for the determination of AAT levels and phe-
notyping was processed. This methodology is applicable to 
all deficient alleles and can be adapted to other populations 
and their more prevalent rare variants.21
The aim of this study was to test the usefulness of this new 
algorithm for AATD Mmalton detection used in our labora-
tory. This is a retrospective review of all AATD determina-
tions performed at the Clinical Laboratory of Hospital Vall 
d´Hebron (Barcelona) over the 2 years after this Mmalton 
allele-specific methodology became available.
Materials and methods
Clinical samples
We performed a retrospective revision of the results obtained 
in all the AATD studies carried out in our laboratory over 
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a 2-year period. All samples were processed according to 
the following algorithm: AAT serum levels were deter-
mined and samples with AAT levels below the established 
cutoff (1.16 g/L) were characterized by phenotyping. In 
case of discrepancy, the Mmalton allele-specific genotyp-
ing assay was performed. All discordant AATD cases were 
analyzed by sequencing of the entire encoding region of the 
SERPINA1 gene.
Serum samples were used to complete the diagnostic 
algorithm except in the case of SERPINA1 sequencing in 
which whole blood samples were required.
The study was approved by the Ethics Committee of the 
Vall d’Hebron Hospital (Barcelona, Spain); as this was a 
retrospective study, and all samples were anonymized, the 
committee did not require informed consent. The study was 
conducted in accordance with the principles of the Declara-
tion of Helsinki, Guidelines for Good Clinical Practice, and 
in full conformity with relevant national regulations.
Detection of Mmalton variants
AAT levels were determined in serum samples by neph-
elometry (Siemens, BNII Instrument, Munich, Germany). 
In order to facilitate the interpretation of the results, each 
laboratory has reference values for AAT concentrations in 
serum samples obtained from a healthy population.22
Phenotyping was performed using the semiautomatic 
Hydrasys System and the Hydragel 18 A1AT Isofocusing kit 
(Sebia, Evry, France),23 designed for the qualitative detection 
and characterization of the different AAT phenotypes.
Genotyping was performed when there was a discrep-
ancy between AAT levels and the phenotype observed. In 
this study, we focused on the search for Mmalton variants. 
Therefore, the candidate samples to be analyzed by the 
Mmalton allele-specific genotyping assay were patients with 
a phenotype showing one or two M alleles, deficient AAT 
serum levels, and without other deficiency alleles detectable 
by phenotyping.
The protocol for Mmalton allele-specific genotyping 
has been described in detail elsewhere.17 In cases in which 
the Mmalton allele was not found, direct sequencing was 
performed after PCR amplification of all the encoding exons 
(II–V) using a whole blood sample.
Results
During the 24 months from January 2014 to December 2015, 
654 subjects were screened. A total of 273 AAT deficiency 
studies were performed in our clinical laboratory in samples 
with serum AAT levels ,1.16 g/L (range: 0.18–1.15 g/L) 
following the algorithm described earlier. All these samples 
were characterized by phenotyping. Samples with one or two 
M alleles and AAT levels discordant with that phenotype 
were analyzed using the Mmalton allele-specific genotyping 
assay. We detected 49 samples with these characteristics; 
7.5% of the total samples and 18% of those with low AAT 
concentrations. Of these, 44 had the MM and five the MS 
phenotype. The AAT concentrations ranged from 0.46 g/L 
to 1.02 g/L. In nine of these samples, the rare Mmalton 
variant was detected in a heterozygous fashion (AAT levels 
ranging from 0.46 g/L to 0.9 g/L). Of these nine Mmalton 
heterozygote samples, eight also carried a normal M variant 
(0.6–0.9 g/L) and one sample carried an S allele (0.46 g/L). 
During the study period, family screenings of previously 
detected M/Mmalton and S/Mmalton individuals were 
performed. In these studies, two relatives of each patient 
were included in the diagnostic algorithm. This allowed 
the identification of four additional Mmalton variants in 
heterozygosity: three M/Mmalton and one S/Mmalton (value 
range: 0.56–0.86 g/L).
Of the 40 remaining deficient samples with the MM and 
MS phenotypes and without Mmalton alleles, we analyzed 
24 by SERPINA1 exonic sequencing. The results showed 
22 cases of MM without exonic mutations, with a range of 
serum concentrations of 0.64–1.02 g/L. Nineteen of these 
22 samples had AAT serum levels close to the limit estab-
lished (range of values: 0.96–1.02 g/L). We also detected two 
M/Null Mattawa (range of values: 0.68 g/L and 0.94 g/L). 
In the remaining 16 cases, we could not obtain a second 
sample to complete the study. The results are shown in 
Tables 1 and 2.
Discussion
We have introduced a new algorithm of AATD diagnosis 
including the Mmalton allele-specific genotyping assay. We 
determined the serum AAT concentrations and phenotypes 
in all the samples attended in the hospital with a request for 
AATD diagnosis over a period of 2 years. The discrepancy 
between the IEF phenotype and AAT serum levels led to 
suspicion of the presence of rare alleles in several cases.24,25 
The Mmalton allele-specific genotyping assay was applied 
in samples that showed one or two M alleles and discor-
dant AAT serum levels, and we detected this rare variant 
in 18% of the cases. Using this method, we avoided the 
sequencing technique, which is quite labor intensive and 
time consuming.
Little is known about the epidemiology of the non-S- and 
non-Z-deficient AAT variants, due to their low prevalence. 
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Table 1 Samples processed by the Mmalton allele-specific genotyping assay
Patient ID 
number
AAT concentrations  
(g/L)
Phenotype Genotype by Mmalton  
allele-specific genotyping
Genotype by SERPINA1 
exonic sequencing
1 0.71 M/M M/Mmalton Not applicable
2 0.67 M/M Mmalton allele undetected no additional WB sample
3 0.89 M/M M/Mmalton Not applicable
4 0.87 M/M M/Mmalton Not applicable
5 0.64 M/M Mmalton allele undetected M/M
6 0.73 M/S Mmalton allele undetected no additional WB sample
7 0.68 M/M Mmalton allele undetected M/Null Mattawa
8 0.76 M/S Mmalton allele undetected no additional WB sample
9 0.9 M/M Mmalton allele undetected M/M
10 0.8 M/S Mmalton allele undetected no additional WB sample
11 0.92 M/M Mmalton allele undetected no additional WB sample
12 0.9 M/M Mmalton allele undetected no additional WB sample
13 0.91 M/M Mmalton allele undetected M/M
14 0.6 M/M M/Mmalton Not applicable
15 0.84 M/S Mmalton allele undetected no additional WB sample
16 0.94 M/M Mmalton allele undetected M/Null Mattawa
17 0.72 M/M Mmalton allele undetected no additional WB sample
18 0.96 M/M Mmalton allele undetected M/M
19 0.96 M/M Mmalton allele undetected M/M
20 0.97 M/M Mmalton allele undetected M/M
21 0.97 M/M Mmalton allele undetected M/M
22 0.98 M/M Mmalton allele undetected M/M
23 0.71 M/M M/Mmalton Not applicable
24 0.98 M/M Mmalton allele undetected M/M
25 0.99 M/M Mmalton allele undetected M/M
26 0.79 M/M Mmalton allele undetected no additional WB sample
27 0.93 M/M Mmalton allele undetected no additional WB sample
28 1 M/M Mmalton allele undetected M/M
29 1 M/M Mmalton allele undetected M/M
30 1 M/M Mmalton allele undetected M/M
31 1 M/M Mmalton allele undetected M/M
32 1.01 M/M Mmalton allele undetected M/M
33 0.81 M/M M/Mmalton Not applicable
34 0.8 M/M Mmalton allele undetected no additional WB sample
35 1.01 M/M Mmalton allele undetected M/M
36 1.01 M/M Mmalton allele undetected M/M
37 0.83 M/M Mmalton allele undetected no additional WB sample
38 0.76 M/M Mmalton allele undetected no additional WB sample
39 1.02 M/M Mmalton allele undetected M/M
40 0.91 M/M Mmalton allele undetected no additional WB sample
41 0.46 M/S S/Mmalton Not applicable
42 1.02 M/M Mmalton allele undetected M/M
43 1.02 MM Mmalton allele undetected M/M
44 0.93 M/M Mmalton allele undetected no additional WB sample
45 0.72 M/M M/Mmalton Not applicable
46 1.02 M/M Mmalton allele undetected M/M
47 1.02 M/M Mmalton allele undetected M/M
48 0.9 M/M M/Mmalton Not applicable
49 0.65 M/M Mmalton allele undetected no additional WB sample
Note: Samples positive for Mmalton detection are shown in bold.
Abbreviations: AAT, alpha-1-antitrypsin; WB, whole blood.
the diagnostic algorithm of AATD with simple molecular 
biology methods such as real-time PCR melting curves. 
This technique is considered one of the fastest and most 
sensitive and reproducible methods.20,27 Indeed, the extremely 
high sensitivity of this technology allows the analysis to be 
A retrospective study of samples obtained in Barcelona from 
1998 to 2010 showed that among these variants, Mmalton 
represented 20% of cases.7 It must be kept in mind that the 
Mmalton variant is difficult to interpret without molecular 
studies.26 For this reason, it is important to complement 
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performed with the very low amount of DNA recovered 
from DBS samples or with the residual DNA that remains 
in standard clinical serum samples. The incorporation of the 
allele-specific genotyping assay for the Mmalton variant in 
the diagnostic algorithm of AATD results in a faster and 
cheaper approach to diagnose this rare allele. In addition, the 
use of the same serum samples available for the determination 
of AAT levels and IEF avoids a new appointment by the 
patient and an additional venopuncture. This practice 
allows a faster diagnosis and avoids the significant delay 
in AATD diagnosis when the SERPINA1 gene sequencing 
method is needed.
Population studies indicate that AATD is an underdiag-
nosed condition, and prolonged delays in diagnosis are 
common.28 Recommendations of the World Health Organiza-
tion and the European Respiratory Society advocate screen-
ing programs for the detection of patients with AATD.29 
In the Spanish population, there is a high frequency of I 
and rare Mmalton AAT variants,7 Mmalton being the more 
deficient than the I variant. In this case, the combination 
of this technique with the habitually used allele-specific 
genotyping assay for detecting the S and Z variants20 in 
large-scale screening programs may increase the number 
of individuals with AATD who are actually diagnosed with 
this disease in Spain. Genotyping using real-time PCR has 
the advantage that a definitive diagnosis is given, and it can 
be adapted for automation. Moreover, routine genotyping 
procedures may be cheaper than other methods for large 
screening programs. For this reason, it would be of interest 
to implement a simple allele-specific genotyping assay to 
study the most prevalent rare variants in each region. This 
could be done with the I variant in Ireland, in which this 
allele accounts for 90% of the total of rare variants,30 or in 
Finland, where the Mmalton variant has not been found, but 
the F allele is the most prevalent rare variant in the Finnish 
population.31,32 Other cases are certain regions of Italy, 
where Mmalton and Mprocida are more prevalent than Z.8 
Bornhorst et al33 reported the M/I phenotype to be associated 
with AAT levels ranging from 0.80 g/L to 1.99 g/L, with 
this variant causing a moderate deficiency. However, the 
F variant presents AAT levels similar to the M variant but 
has reduced functional ability to inhibit neutrophil elastase 
compared to the normal allele.34 In our case, we found the 
Mmalton variant in combination with the M allele with 
AAT levels ranging from 0.6 g/L to 0.9 g/L. Most of the 
M/Mmalton individuals described have normal pulmonary 
functions, while Z/Mmalton patients often have a high risk 
of developing emphysema, especially smokers.35,36 Mprocida 
is another rare deficiency variant with IEF mobility similar 
to the M allele, which has been reported to produce 3%–4% 
of the normal amount of AAT.37,38
In this study, we have described a new diagnostic algo-
rithm that has been used for 24 months with the samples 
received for AAT study. This new algorithm was comput-
erized and provided definitive results even using serum 
samples. In this sense, it should be kept in mind that serum 
samples are used for routine determination of AAT levels 
and phenotyping. Therefore, the use of these samples 
for specific genotyping avoids the significant delay in 
diagnosis when a new whole blood sample is required for 
further molecular characterizations. A new appointment 
with the patient requires weeks or even months, while the 
use of the same serum sample significantly accelerates the 
routine diagnostic process. In fact, a significant number 
of patients did not provide a second sample for analysis 
in our study.
Table 2 Mmalton heterozygote samples detected using the Mmalton allele-specific genotyping assay
Patient Origin AAT concentrations (g/L) Phenotype Genotype
1 routine 0.71 M/M M/Mmalton
2 routine 0.89 M/M M/Mmalton
3 routine 0.87 M/M M/Mmalton
4 routine 0.60 M/M M/Mmalton
5 routine 0.71 M/M M/Mmalton
6 routine 0.81 M/M M/Mmalton
7 routine 0.46 M/S S/Mmalton
8 routine 0.72 M/M M/Mmalton
9 routine 0.9 M/M M/Mmalton
10 Family study of patient 1 0.72 M/M M/Mmalton
11 Family study of patient 1 0.56 M/S S/Mmalton
12 Family study of patient 7 0.77 M/M M/Mmalton
13 Family study of patient 7 0.86 M/M M/Mmalton
Abbreviation: AAT, alpha-1-antitrypsin.
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The detection of Mmalton variants is relevant because 
patients with homozygote Mmalton or Z/Mmalton genotypes 
with evidence of emphysema are candidates to receive aug-
mentation therapy. Even some cases of S/Mmalton or in com-
bination with other deficient alleles that show serum AAT 
levels ,11 µM would fulfill the internationally accepted 
criteria for initiation of this therapy.29
Conclusion
The incorporation of the Mmalton allele-specific genotyping 
assay in the diagnostic algorithm of AATD could allow the 
clinical characterization of Mmalton individuals who, to date, 
are not well characterized. Our results show the strong need to 
develop standardized algorithms to obtain conclusive data of the 
real incidence of rare AAT variants in each country or region.
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